{
    "info": {
        "nct_id": "NCT03404193",
        "official_title": "A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "inclusion_criteria": "* Patients with AML, BPDCN, biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) who have failed prior therapy; patients with AML should have failed prior therapy or have relapsed after prior therapy; patients with isolated extramedullary AML are eligible\n* Elderly (> 60 year old) patients with newly diagnosed AML, BPDCN, or mixed phenotype acute leukemia (MPAL) not eligible for intensive chemotherapy\n* Patients with newly diagnosed AML with poor risk complex karyotype and/or TP53 deletions/mutations equal or younger than 60 year old\n* AML or BPDCN patients with prior history of MDS or CMML who received any therapy or no therapy for the MDS or CMML and progressed to AML, are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS; the World Health Organization (WHO) classification will be used for AML\n* Patients with high-risk MDS with bone marrow blasts between 10% and 20%, relapsed or refractory to prior hypomethylating agent (HMA) therapy, defined as prior receipt of 4 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy; patients with high risk chronic myelomonocytic leukemia (CMML) with bone marrow blasts >= 10% regardless of prior therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 3\n* White blood cell count =< 10,000\n* Adequate renal function including creatinine < 2 unless related to the disease\n* Adequate hepatic function including total bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\n* Alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement\n* Provision of written informed consent\n* Oral hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and while the patient is on active study treatment through cycle 1, as needed, for clinical benefit and after discussion with the principal investigator (PI); concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\n* Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment\n* Women of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients having received any prior BCL2 inhibitor therapy\n* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\n* Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\n* Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\n* Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\n* Pregnant or breastfeeding",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Elderly (> 60 year old) patients with newly diagnosed AML, BPDCN, or mixed phenotype acute leukemia (MPAL) not eligible for intensive chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Elderly (> 60 year old) patients",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed AML, BPDCN, or mixed phenotype acute leukemia (MPAL)",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "acute myeloid leukemia (AML)",
                                "blastic plasmacytoid dendritic cell neoplasm (BPDCN)",
                                "mixed phenotype acute leukemia (MPAL)"
                            ]
                        },
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "not eligible for intensive chemotherapy",
                    "criterion": "eligibility for intensive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with AML, BPDCN, biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) who have failed prior therapy; patients with AML should have failed prior therapy or have relapsed after prior therapy; patients with isolated extramedullary AML are eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients with AML, BPDCN, biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL)",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "AML",
                                "BPDCN",
                                "biphenotypic leukemia",
                                "bilineage leukemia (including a myeloid component)",
                                "mixed phenotype acute leukemia (MPAL)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "who have failed prior therapy",
                    "criterion": "prior therapy failure",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "failed"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with AML should have failed prior therapy or have relapsed after prior therapy",
                    "criterion": "AML prior therapy response",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "failed prior therapy",
                                "relapsed after prior therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with isolated extramedullary AML are eligible",
                    "criterion": "isolated extramedullary AML",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with newly diagnosed AML with poor risk complex karyotype and/or TP53 deletions/mutations equal or younger than 60 year old",
            "criterions": [
                {
                    "exact_snippets": "newly diagnosed AML",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "poor risk complex karyotype",
                    "criterion": "complex karyotype",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "poor risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "TP53 deletions/mutations",
                    "criterion": "TP53 gene status",
                    "requirements": [
                        {
                            "requirement_type": "deletion or mutation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "equal or younger than 60 year old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AML or BPDCN patients with prior history of MDS or CMML who received any therapy or no therapy for the MDS or CMML and progressed to AML, are eligible at the time of diagnosis of AML regardless of any prior therapy for MDS; the World Health Organization (WHO) classification will be used for AML",
            "criterions": [
                {
                    "exact_snippets": "AML or BPDCN patients",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "AML",
                                "BPDCN"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of MDS or CMML",
                    "criterion": "prior history of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "MDS",
                                "CMML"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "who received any therapy or no therapy for the MDS or CMML",
                    "criterion": "prior therapy for MDS or CMML",
                    "requirements": [
                        {
                            "requirement_type": "therapy history",
                            "expected_value": "any or none"
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed to AML",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "to AML"
                        }
                    ]
                },
                {
                    "exact_snippets": "are eligible at the time of diagnosis of AML",
                    "criterion": "timing of eligibility",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of AML diagnosis"
                        }
                    ]
                },
                {
                    "exact_snippets": "the World Health Organization (WHO) classification will be used for AML",
                    "criterion": "diagnostic classification system",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "WHO for AML"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 3",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with high-risk MDS with bone marrow blasts between 10% and 20%, relapsed or refractory to prior hypomethylating agent (HMA) therapy, defined as prior receipt of 4 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy; patients with high risk chronic myelomonocytic leukemia (CMML) with bone marrow blasts >= 10% regardless of prior therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients with high-risk MDS",
                    "criterion": "myelodysplastic syndrome (MDS) risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "high-risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone marrow blasts between 10% and 20%",
                    "criterion": "bone marrow blast percentage (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "%"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 20,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed or refractory to prior hypomethylating agent (HMA) therapy, defined as prior receipt of 4 cycles of HMA therapy with failure to attain a response, or relapse after prior response to HMA therapy",
                    "criterion": "response to prior hypomethylating agent (HMA) therapy (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        },
                        {
                            "requirement_type": "response to therapy",
                            "expected_value": [
                                "refractory",
                                "relapsed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with high risk chronic myelomonocytic leukemia (CMML)",
                    "criterion": "chronic myelomonocytic leukemia (CMML) risk category",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "high risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone marrow blasts >= 10%",
                    "criterion": "bone marrow blast percentage (CMML)",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell count =< 10,000",
            "criterions": [
                {
                    "exact_snippets": "White blood cell count =< 10,000",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10000,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function including creatinine < 2 unless related to the disease",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine < 2 unless related to the disease",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless related to the disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function including total bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "Gilbert's disease",
                                "leukemic involvement"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) < 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless considered due to leukemic involvement",
                    "criterion": "elevated alanine aminotransferase (ALT) due to leukemic involvement",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "leukemic involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provision of written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provision of written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "format",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Oral hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and while the patient is on active study treatment through cycle 1, as needed, for clinical benefit and after discussion with the principal investigator (PI); concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
            "criterions": [
                {
                    "exact_snippets": "Oral hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy and while the patient is on active study treatment through cycle 1, as needed, for clinical benefit and after discussion with the principal investigator (PI)",
                    "criterion": "use of oral hydroxyurea and/or one dose of cytarabine",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "before the start of study therapy",
                                "while the patient is on active study treatment through cycle 1"
                            ]
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "rapidly proliferative disease"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "g/m^2"
                            }
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": "after discussion with the principal investigator (PI)"
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
                    "criterion": "concurrent CNS-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": [
                                "CNS prophylaxis",
                                "continuation of therapy for controlled CNS disease"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment; males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment",
                    "criterion": "contraception use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study and until 3 months after the last treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment",
                    "criterion": "sterility or contraception use (males)",
                    "requirements": [
                        {
                            "requirement_type": "sterility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the study until 3 months after the last treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment",
            "criterions": [
                {
                    "exact_snippets": "Females must be surgically or biologically sterile",
                    "criterion": "female sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization_status",
                            "expected_value": [
                                "surgically sterile",
                                "biologically sterile"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Females must be ... postmenopausal (amenorrheic for at least 12 months)",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "amenorrhea_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment",
                    "criterion": "pregnancy status (for females of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy_test_result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "pregnancy_test_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours before treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator",
                    "criterion": "medical, psychological, or social condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance or compromise patient safety",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": "in the opinion of the investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia",
            "criterions": [
                {
                    "exact_snippets": "Patients with symptomatic CNS leukemia",
                    "criterion": "CNS leukemia",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with poorly controlled CNS leukemia",
                    "criterion": "CNS leukemia",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients having received any prior BCL2 inhibitor therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients having received any prior BCL2 inhibitor therapy",
                    "criterion": "prior BCL2 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
            "criterions": [
                {
                    "exact_snippets": "t(15;17) karyotypic abnormality",
                    "criterion": "t(15;17) karyotypic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
                    "criterion": "acute promyelocytic leukemia (FAB class M3-AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "known infection with human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "active and uncontrolled comorbidities including active uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension despite adequate medical therapy",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant and uncontrolled arrhythmia as judged by the treating physician",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}